Age and sex as moderators of the placebo response - An evaluation of systematic reviews and meta-analyses across medicine

Gerontology

Volumn 61, Issue 2, 2015, Pages 97-108

  Weimer, Katja ^a   Colloca, Luana ^b   Enck, Paul ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Age; Meta analyses; Placebo response; Randomized controlled trials; Sex

Indexed keywords

AGE; ARTICLE; DATA BASE; DEPRESSION; DISEASE SEVERITY; EVALUATION STUDY; GASTROINTESTINAL DISEASE; HUMAN; META ANALYSIS; NEUROLOGIC DISEASE; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; SEX DIFFERENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; ADULT; AGED; DRUG THERAPY; FEMALE; MALE; PROCEDURES; SEVERITY OF ILLNESS INDEX; SEX; STATISTICS AND NUMERICAL DATA;

ADULT; AGE FACTORS; AGED; DRUG THERAPY; FEMALE; HUMANS; MALE; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SEX;

EID: 84924255392     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000365248     Document Type: Article

References (110)

1. de Craen AJ, Kaptchuk TJ, Tijssen JG, Kleijnen J: Placebos and placebo effects in medicine: historical overview. J R Soc Med 1999; 92: 511-515.
2. Miller FG, Colloca L: The placebo phenomenon and medical ethics: rethinking the relationship between informed consent and riskbenefit assessment. Theor Med Bioeth 2011; 32: 229-243.
3. Weimer K, Enck P: Traditional and innovative experimental and clinical trial designs-advantages and pitfalls. Handb Exp Pharmacol 2014; 225: 237-272.
4. Enck P, Bingel U, Schedlowski M, Rief W: The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013; 12: 191-204.
5. Kaptchuk TJ, Kelley JM, Deykin A, Wayne PM, Lasagna LC, Epstein IO, Kirsch I, Wechsler ME: Do placebo responders exist? Contemp Clin Trials 2008; 29: 587-595.
6. Horing B, Weimer K, Enck P: Predictors of placebo effects across symptoms and symptom modalities. Psychosom Med 2014; 76: A29.
7. Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, Conboy LA, Kelley JM, Kokkotou E, Kaptchuk TJ: Catechol-Omethyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 2012; 7:e48135.
8. Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C, Pissiota A, Frans O, Bani M, Bettica P, Pich EM, Jacobsson E, Wahlstedt K, Oreland L, Långström B, Eriksson E, Fredrikson M: A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci 2008; 28: 13066-13074.
9. Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE: Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol 2009; 29: 372-377.
10. Yu R, Gollub RL, Vangel M, Kaptchuk T, Smoller JW, Kong J: Placebo analgesia and reward processing: integrating genetics, personality, and intrinsic brain activity. Hum Brain Mapp DOI: 10.1002/hbm.22496.
11. Enck P, Klosterhalfen S: The story of O-is oxytocin the mediator of the placebo response? Neurogastroenterol Motil 2009; 21: 347-350.
12. Kessner S, Sprenger C, Wrobel N, Wiech K, Bingel U: Effect of oxytocin on placebo analgesia: a randomized study. JAMA 2013; 310: 1733-1735.
13. Franconi F, Campesi I, Occhioni S, Antonini P, Murphy MF: Sex and gender in adverse drug events, addiction, and placebo. Handb Exp Pharmacol 2012; 214: 107-126.
14. Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI: Efficacy of antidepressants for late-life depression: a metaanalysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 2011; 72: 1660-1668.
15. Rutherford BR, Tandler J, Brown PJ, Sneed JR, Roose SP: Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome. Am J Geriatr Psychiatry 2013;pii:S1064-7481(13)00350-3.
16. Weimer K, Gulewitsch MD, Schlarb AA, Schwille-Kiuntke J, Klosterhalfen S, Enck P: Placebo effects in children: a review. Pediatr Res 2013; 74: 96-102.
17. Fadai T: Placebo analgesia in children compared to adults (poster); in IASP Congr, Milan, August 2012.
18. Cherniack EP: Would the elderly be better off if they were given more placebos? Geriatr Gerontol Int 2010; 10: 131-137.
19. Bingel U, Colloca L, Vase L: Mechanisms and clinical implications of the placebo effect: is there a potential for the elderly? A mini-review. Gerontology 2011; 57: 354-363.
20. Kunz M, Rainville P, Lautenbacher S: Operant conditioning of facial displays of pain. Psychosom Med 2011; 73: 422-431.
21. Burneo JG, Montori VM, Faught E: Magnitude of the placebo effect in randomized trials of antiepileptic agents. Epilepsy Behav 2002; 3: 532-534.
22. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P: Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med 2008; 5:e166.
23. Schmidt D, Beyenburg S, DSouza J, Stavem K: Clinical features associated with placebo response in refractory focal epilepsy. Epilepsy Behav 2013; 27: 393-398.
24. Fulda S, Wetter TC: Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008; 131: 902-917.
25. Ondo WG, Hossain MM, Gordon MF, Reess J: Predictors of placebo response in restless legs syndrome studies. Neurology 2013; 81: 193-194.
26. Goetz CG, Leurgans S, Raman R, Stebbins GT: Objective changes in motor function during placebo treatment in PD. Neurology 2000; 54: 710-714.
27. Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O, Russ H: Placebo influences on dyskinesia in Parkinsons disease. Mov Disord 2008; 23: 700-707.
28. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Parkinson Study Group, Leurgans S: Placebo response in Parkinsons disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008; 23: 690-699.
29. Ondo WG: Placebo response in Parkinson trials using patient diaries: sites do matter. Clin Neuropharmacol 2007; 30: 301-304.
30. Diener HC, Dowson AJ, Ferrari M, Nappi G, Tfelt-Hansen P: Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 1999; 19: 699-700.
31. Macedo A, Farré M, Baños JE: A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur J Clin Pharmacol 2006; 62: 161-172.
32. Macedo A, Baños JE, Farré M: Placebo response in the prophylaxis of migraine: a metaanalysis. Eur J Pain 2008; 12: 68-75.
33. Ho TW, Fan X, Rodgers A, Lines CR, Winner P, Shapiro RE: Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults. Cephalalgia 2009; 29: 711-718.
34. Sun H, Bastings E, Temeck J, Smith PB, Men A, Tandon V, Murphy D, Rodriguez W: Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. JAMA Pediatr 2013; 167: 243-249.
35. Meissner K, Fässler M, Rücker G, Kleijnen J, Hróbjartsson A, Schneider A, Antes G, Linde K: Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern Med 2013; 173: 1941-1951.
36. Averbuch M, Katzper M: Gender and the placebo analgesic effect in acute pain. Clin Pharmacol Ther 2001; 70: 287-291.
37. Quessy SN, Rowbotham MC: Placebo response in neuropathic pain trials. Pain 2008; 138: 479-483.
38. Kamper SJ, Machado LA, Herbert RD, Maher CG, McAuley JH: Trial methodology and patient characteristics did not influence the size of placebo effects on pain. J Clin Epidemiol 2008; 61: 256-260.
39. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M: The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 1716-1723.
40. Häuser W, Bartram-Wunn E, Bartram C, Reinecke H, Tölle T: Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain 2011; 152: 1709-1717.
41. Capurso G, Cocomello L, Benedetto U, Cammà C, Delle Fave G: Meta-analysis: the placebo rate of abdominal pain remission in clinical trials of chronic pancreatitis. Pancreas 2012; 41: 1125-1131.
42. Woods SW, Gueorguieva RV, Baker CB, Makuch RW: Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry 2005; 62: 961-970.
43. Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dubé S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A: What is causing the reduced drug placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 2010; 36: 504-509.
44. Mallinckrodt CH, Zhang L, Prucka WR, Millen BA: Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 2010; 43: 53-72.
45. Chen YF, Wang SJ, Khin NA, Hung HM, Laughren TP: Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat 2010; 9: 217-229.
46. Potkin S, Agid O, Siu C, Watsky E, Vanderburg D, Remington G: Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia. Schizophr Res 2011; 132: 108-113.
47. Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D, Zipursky RB, Remington G: Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry 2013; 170: 1335-1344.
48. King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F, Sullivan L, Hirtz D: Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr 2013; 167: 1045-1052.
49. Sysko R, Walsh BT: A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry 2007; 68: 1213-1217.
50. Yildiz A, Vieta E, Tohen M, Baldessarini RJ: Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol 2011; 14: 863-875.
51. Cohen D, Consoli A, Bodeau N, Purper-Ouakil D, Deniau E, Guile JM, Donnelly C: Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J Child Adolesc Psychopharmacol 2010; 20: 39-47.
52. Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, Dsouza DN, Schuh LM, Allen AJ: Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child AdolescPsychiatry 2009; 48: 1165-1172.
53. Waxmonsky JG, Waschbusch DA, Glatt SJ, Faraone SV: Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. J Clin Psychiatry 2011; 72: 1366-1375.
54. Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B: Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. J Clin Psychiatry 2012; 73: 1097-1102.
55. Blom TJ, Mingione CJ, Guerdjikova AI, Keck PE Jr, Welge JA, McElroy SL: Placebo response in binge eating disorder: a pooled analysis of 10 clinical trials from one research group. Eur Eat Disord Rev 2014; 22: 140-146.
56. Greene NM, Taylor EM, Gage SH, Munafò MR: Industry funding and placebo quit rate in clinical trials of nicotine replacement therapy: a commentary on Etter et al. (2007). Addiction 2010; 105: 2217-2218.
57. Litten RZ, Castle IJ, Falk D, Ryan M, Fertig J, Chen CM, Yi HY: The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res 2013; 37: 2128-2137.
58. Moore RA, Aubin HJ: Do placebo response rates from cessation trials inform on strength of addictions? Int J Environ Res Public Health 2012; 9: 192-211.
59. Brown WA, Johnson MF, Chen MG: Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res 1992; 41: 203-214.
60. Walsh BT, Seidman SN, Sysko R, Gould M: Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-1847.
61. Khan A, Leventhal RM, Khan SR, Brown WA: Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22: 40-45.
62. Evans KR, Sills T, Wunderlich GR, McDonald HP: Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders? J Psychiatr Res 2004; 38: 437-444.
63. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B: Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67: 1741-1746.
64. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT: Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5:e45.
65. Papakostas GI, Fava M: Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19: 34-40.
66. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA: Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166: 42-49.
67. Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F: Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One 2009; 4:e4824.
68. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL: Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and metaanalyses. J Clin Psychiatry 2010; 71: 270-279.
69. Hunter AM, Cook IA, Leuchter AF: Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression. J Clin Psychopharmacol 2010; 30: 748-751.
70. Rutherford BR, Sneed JR, Tandler JM, Rindskopf D, Peterson BS, Roose SP: Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact. J Am Acad Child Adolesc Psychiatry 2011; 50: 782-795.
71. Gueorguieva R, Mallinckrodt C, Krystal JH: Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry 2011; 68: 1227-1237.
72. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP: Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011; 72: 464-472.
73. Mancini M, Wade AG, Perugi G, Lenox-Smith A, Schacht A: Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. J Psychiatr Res 2014; 51: 21-29.
74. Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN: Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 1854-1858.
75. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD: A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004; 126: 1257-1269.
76. Renna S, Cammà C, Modesto I, Cabibbo G, Scimeca D, Civitavecchia G, Mocciaro F, Orlando A, Enea M, Cottone M: Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008; 135: 1500-1509.
77. Pitz M, Cheang M, Bernstein CN: Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 237-247.
78. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, Canenguez K, Park JK, Kelly E, Jacobson E, Kerr CE, Lembo AJ: The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-340.
79. Dorn SD, Kaptchuk TJ, Park JB, Nguyen LT, Canenguez K, Nam BH, Woods KB, Conboy LA, Stason WB, Lembo AJ: A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 630-637.
80. Ford AC, Moayyedi P: Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 144-158.
81. Talley NJ, Locke GR, Lahr BD, Zinsmeister AR, Cohard-Radice M, D'Elia TV, Tack J, Earnest DL: Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 2006; 23: 923-936.
82. Enck P, Vinson B, Malfertheiner P, Zipfel S, Klosterhalfen S: The placebo response in functional dyspepsia-reanalysis of trial data. Neurogastroenterol Motil 2009; 21: 370-377.
83. de Craen AJ, Moerman DE, Heisterkamp SH, Tytgat GN, Tijssen JG, Kleijnen J: Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol 1999; 48: 853-860.
84. Yuan YH, Wang C, Yuan Y, Hunt RH: Metaanalysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials. Aliment Pharmacol Ther 2009; 30: 197-209.
85. Cremonini F, Ziogas DC, Chang HY, Kokkotou E, Kelley JM, Conboy L, Kaptchuk TJ, Lembo AJ: Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 29-42.
86. Lee S, Malhotra B, Creanga D, Carlsson M, Glue P: A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol 2009; 9: 55.
87. Thijs L, Amery A, Birkenhäger W, Bulpitt CJ, Clement D, de Leeuw P, De Schaepdryver A, Dollery C, Forette F, Henry JF, et al: Age-related effects of placebo and active treatment in patients beyond the age of 60 years: the need for a proper control group. J Hypertens 1990; 8: 997-1002.
88. Cho HJ, Hotopf M, Wessely S: The placebo response in the treatment of chronic fatigue syndrome: a systematic review and metaanalysis. Psychosom Med 2005; 67: 301-313.
89. Freeman EW, Rickels K: Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999; 156: 1403-1408.
90. Lamel SA, Myer KA, Younes N, Zhou JA, Maibach H, Maibach HI: Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment. Arch Dermatol Res 2012; 304: 707-717.
91. Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M: The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy 2013; 3: 42.
92. Kemeny ME, Rosenwasser LJ, Panettieri RA, Rose RM, Berg-Smith SM, Kline JN: Placebo response in asthma: a robust and objective phenomenon. J Allergy Clin Immunol 2007; 119: 1375-1381.
93. Wang X, Shang D, Ribbing J, Ren Y, Deng C, Zhou T, Guo F, Lu W: Placebo effect model in asthma clinical studies: longitudinal metaanalysis of forced expiratory volume in 1 second. Eur J Clin Pharmacol 2012; 68: 1157-1166.
94. McCall WV, D'Agostino R Jr, Dunn A: A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 2003; 4: 57-62.
95. McCall WV, D'Agostino R Jr, Rosenquist PB, Kimball J, Boggs N, Lasater B, Blocker J: Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs. Sleep Med 2011; 12: 557-564.
96. Tudur Smith C, Dwan K, Altman DG, Clarke M, Riley R, Williamson PR: Sharing individual participant data from clinical trials: an opinion survey regarding the establishment of a central repository. PLoS One 2014; 9: e97886.
97. Krogsbøll LT, Hróbjartsson A, Gøtzsche PC: Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol 2009; 9: 1.
98. Hofstra WB, Sterk PJ, Neijens HJ, Kouwenberg JM, Duiverman EJ: Prolonged recovery from exercise-induced asthma with increasing age in childhood. Pediatr Pulmonol 1995; 20: 177-183.
99. Furukawa TA, Noma H, Caldwell DM, Honyashiki M, Shinohara K, Imai H, Chen P, Hunot V, Churchill R: Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand 2014; 130: 181-192.
100. Rutherford BR, Mori S, Sneed JR, Pimontel MA, Roose SP: Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. J Psychiatr Res 2012; 46: 697-702.
101. Posternak MA, Miller I: Untreated shortterm course of major depression: a metaanalysis of outcomes from studies using wait-list control groups. J Affect Disord 2001; 66: 139-146.
102. Hróbjartsson A, Gøtzsche PC: Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010;CD003974.
103. Meissner K: Preferring patient-reported to observer-reported outcomes substantially influences the results of the updated systematic review on placebos by Hróbjartsson and Gøtzsche. J Intern Med 2005; 257: 394.
104. Kobak KA, Kane JM, Thase ME, Nierenberg AA: Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 2007; 27: 1-5.
105. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG: Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009; 118: 1-8.
106. Kirsch I: The emperor's new drugs: medication and placebo in the treatment of depression. Handb Exp Pharmacol 2014; 225: 291-303.
107. Grelotti DJ, Kaptchuk TJ: Placebo by proxy. BMJ 2011; 343:d4345.
108. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernandez R, Phillips AG, Stoessl J: Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010; 67: 857-865.
109. Lou JS, Dimitrova DM, Hammerschlag R, Nutt J, Hunt EA, Eaton RW, Johnson SC, Davis MD, Arnold GC, Andrea SB, Oken BS: Effect of expectancy and personality on cortical excitability in Parkinson's disease. Mov Disord 2013; 28: 1257-1262.
110. Gøtzsche PC, Hróbjartsson A, Maric K, Tendal B: Data extraction errors in meta-analyses that use standardized mean differences. JAMA 2007; 29: 430-437.